Albert Enz

4.5k total citations · 1 hit paper
68 papers, 3.7k citations indexed

About

Albert Enz is a scholar working on Molecular Biology, Pharmacology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Albert Enz has authored 68 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Molecular Biology, 26 papers in Pharmacology and 24 papers in Cellular and Molecular Neuroscience. Recurrent topics in Albert Enz's work include Cholinesterase and Neurodegenerative Diseases (25 papers), Neuroscience and Neuropharmacology Research (14 papers) and Receptor Mechanisms and Signaling (11 papers). Albert Enz is often cited by papers focused on Cholinesterase and Neurodegenerative Diseases (25 papers), Neuroscience and Neuropharmacology Research (14 papers) and Receptor Mechanisms and Signaling (11 papers). Albert Enz collaborates with scholars based in Switzerland, United States and United Kingdom. Albert Enz's co-authors include Roger Lane, Steven G. Potkin, Jan Malanowski, G. Gmelin, Angela Guillozet-Bongaarts, Clive Ballard, Nigel H. Greig, Sultan Darvesh, René Spiegel and René Amstutz and has published in prestigious journals such as Journal of Neuroscience, Nature Biotechnology and The Journal of Immunology.

In The Last Decade

Albert Enz

68 papers receiving 3.6k citations

Hit Papers

Targeting acetylcholinesterase and butyrylcholinesterase ... 2005 2026 2012 2019 2005 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Targeting acetylcholinesterase and butyrylcholinesterase in dementia
    2005 538 citations Roger Lane, Steven G. Potkin et al. The International Journal of Neuropsychopharmacology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Albert Enz Switzerland 31 1.9k 1.2k 838 832 751 68 3.7k
Harold W. Holloway United States 40 2.2k 1.2× 1.6k 1.3× 960 1.1× 1.3k 1.5× 1.2k 1.6× 78 5.7k
Hachiro Sugimoto Japan 40 1.8k 1.0× 1.7k 1.4× 808 1.0× 831 1.0× 1.1k 1.5× 104 4.6k
Sultan Darvesh Canada 35 2.8k 1.5× 1.3k 1.1× 499 0.6× 1.7k 2.0× 967 1.3× 116 4.6k
Mike Snape United States 16 1.2k 0.6× 899 0.7× 631 0.8× 367 0.4× 746 1.0× 25 2.7k
Orly Weinreb Israel 41 1.4k 0.7× 1.7k 1.4× 1.1k 1.3× 472 0.6× 1.7k 2.3× 103 6.4k
G K Wilcock United Kingdom 14 1.5k 0.8× 753 0.6× 572 0.7× 410 0.5× 1.3k 1.8× 22 3.6k
С. О. Бачурин Russia 35 1.5k 0.8× 1.5k 1.3× 607 0.7× 767 0.9× 1.1k 1.5× 220 4.2k
Ramón Cacabelos Spain 44 1.5k 0.8× 2.0k 1.7× 839 1.0× 924 1.1× 2.3k 3.0× 270 6.8k
Barbara Malawska Poland 30 1.8k 1.0× 1.2k 1.0× 465 0.6× 1.3k 1.6× 1.0k 1.3× 141 3.8k
Stephen Brimijoin United States 43 3.1k 1.7× 2.2k 1.8× 1.9k 2.3× 1.4k 1.7× 1.1k 1.5× 180 6.3k

Countries citing papers authored by Albert Enz

Since Specialization
Citations

This map shows the geographic impact of Albert Enz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Albert Enz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Albert Enz more than expected).

Fields of papers citing papers by Albert Enz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Albert Enz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Albert Enz. The network helps show where Albert Enz may publish in the future.

Co-authorship network of co-authors of Albert Enz

This figure shows the co-authorship network connecting the top 25 collaborators of Albert Enz. A scholar is included among the top collaborators of Albert Enz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Albert Enz. Albert Enz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Troxler, Thomas, Konstanze Hurth, Henri Mattes, et al.. (2009). Discovery of novel non-peptidic β-alanine piperazine amide derivatives and their optimization to achiral, easily accessible, potent and selective somatostatin sst1 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 19(5). 1305–1309. 11 indexed citations
2.
Feuerbach, Dominik, Kurt Lingenhoehl, Hans-Rudolf Olpe, et al.. (2008). The selective nicotinic acetylcholine receptor α7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain. Neuropharmacology. 56(1). 254–263. 103 indexed citations
3.
4.
Lefèvre, Gilbert, G Sędek, S. S. Jhee, et al.. (2007). Pharmacokinetics and Pharmacodynamics of the Novel Daily Rivastigmine Transdermal Patch Compared With Twice-daily Capsules in Alzheimer's Disease Patients. Clinical Pharmacology & Therapeutics. 83(1). 106–114. 106 indexed citations
5.
Hurth, Konstanze, Albert Enz, Philipp Floersheim, et al.. (2007). SAR of the arylpiperazine moiety of obeline somatostatin sst1 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 17(14). 3988–3991. 8 indexed citations
6.
Lane, Roger, Steven G. Potkin, & Albert Enz. (2005). Targeting acetylcholinesterase and butyrylcholinesterase in dementia. The International Journal of Neuropsychopharmacology. 9(1). 101–101. 538 indexed citations breakdown →
7.
Hintersteiner, Martin, Albert Enz, Pascal Frey, et al.. (2005). In vivo detection of amyloid-β deposits by near-infrared imaging using an oxazine-derivative probe. Nature Biotechnology. 23(5). 577–583. 284 indexed citations
8.
Giacobini, Ezio, René Spiegel, Albert Enz, Amy E. Veroff, & Neal R. Cutler. (2002). Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit. Journal of Neural Transmission. 109(7-8). 1053–1065. 191 indexed citations
9.
Kennedy, John, Ronald J. Polinsky, Benjamin Johnson, et al.. (1999). Preferential Cerebrospinal Fluid Acetylcholinesterase Inhibition by Rivastigmine in Humans. Journal of Clinical Psychopharmacology. 19(6). 513–521. 63 indexed citations
10.
Quesniaux, Valérie, Jean‐Jacques Sanglier, Lukas Oberer, et al.. (1997). Cymbimicin A and B, Two Novel Cyclophilin-binding Structures Isolated from Actinomycetes.. The Journal of Antibiotics. 50(11). 893–899. 13 indexed citations
11.
Enz, Albert & Esteban Pombo‐Villar. (1997). Class II pyrethroids: Noninhibitors calcineurin. Biochemical Pharmacology. 54(2). 321–323. 21 indexed citations
12.
13.
Enz, Albert, René Amstutz, H. W. G. M. Boddeke, G. Gmelin, & Jan Malanowski. (1993). Chapter 53: Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease. Progress in brain research. 98. 431–438. 252 indexed citations
14.
Enz, Albert, et al.. (1993). SDZ ENS 163 a novel pilocarpine like drug: Pharmacological in vitro and in vivo profile. Life Sciences. 52(5-6). 513–520. 9 indexed citations
15.
Boddeke, H. W. G. M., Manuel Buttini, M. Lichtsteiner, & Albert Enz. (1992). M1 muscarinic receptors mediate intracellular calcium release in NB-OK1 human neuroblastoma cells. Naunyn-Schmiedeberg s Archives of Pharmacology. 346(3). 255–61. 3 indexed citations
16.
Enz, Albert, Gideon Shapiro, Porntip Supavilai, & H.W.G.M. Boddeke. (1992). SDZ ENS 163 is a selective M1 agonist and induces release of acetylcholine. Naunyn-Schmiedeberg s Archives of Pharmacology. 345(3). 282–7. 7 indexed citations
17.
Enz, Albert, Hendrikus Boddeke, Julian Gray, & René Spiegel. (1991). Pharmacologic and Clinicopharmacologic Properties of SDZ ENA 713, a Centrally Selective Acetylcholinesterase Inhibitor. Annals of the New York Academy of Sciences. 640(1). 272–275. 54 indexed citations
18.
Gähwiler, B.H., Lotty Rietschin, Thomas Knöpfel, & Albert Enz. (1990). Continuous presence of nerve growth factor is required for maintenance of cholinergic septal neurons in organotypic slice cultures. Neuroscience. 36(1). 27–31. 41 indexed citations
19.
Flückiger, E., U. Briner, Barbara J. Clark, et al.. (1988). Pharmacodynamic profile of CQP 201-403, a novel 8α-amino-ergoline. Cellular and Molecular Life Sciences. 44(5). 431–436. 9 indexed citations
20.
Büscher, Heinz H., D. Römer, Richard A. Maurer, et al.. (1988). CY 208–243: A unique combination of atypical opioid antinociception and D1 dopaminomimetic properties. Life Sciences. 42(2). 137–152. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Harold W. Holloway Breakdown of academic impact, for papers by Hachiro Sugimoto Breakdown of academic impact, for papers by Sultan Darvesh Breakdown of academic impact, for papers by Mike Snape Breakdown of academic impact, for papers by Orly Weinreb Breakdown of academic impact, for papers by G K Wilcock Breakdown of academic impact, for papers by С. О. Бачурин Breakdown of academic impact, for papers by Ramón Cacabelos Breakdown of academic impact, for papers by Barbara Malawska Breakdown of academic impact, for papers by Stephen Brimijoin
Rankless by CCL
2026